View in EDS

Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial

Saved in:
Bibliographic Details
Title: Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial
Authors: Öcal, Osman, Schütte, Kerstin, Kupčinskas, Juozas, Morkunas, Egidijus, Jurkeviciute, Gabija, De Toni, Enrico N, Ben Khaled, Najib, Berg, Thomas, Malfertheiner, Peter, Klümpen, Heinz Josef, Sengel, Christian, Basu, Bristi, Valle, Juan W, Benckert, Julia, Gasbarrini, Antonio, Palmer, Daniel, Seidensticker, Ricarda, Wildgruber, Moritz, Sangro, Bruno, Pech, Maciej, Ricke, Jens, Seidensticker, Max
Contributors: DSpace at Cambridge pro (8.1)
Source: J Cancer Res Clin Oncol
Publisher Information: Springer Science and Business Media LLC, 2021.
Publication Year: 2021
Subject Terms: Adult, Male, 0301 basic medicine, Carcinoma, Hepatocellular, Adolescent, Turkey, Hepatocellular carcinoma, Original Article – Clinical Oncology, Carcinoma, Hepatocellular/mortality [MeSH], Disease Progression [MeSH], Aged, 80 and over [MeSH], Liver Neoplasms/mortality [MeSH], Turkey/epidemiology [MeSH], Aged [MeSH], Sorafenib, Liver Neoplasms/pathology [MeSH], Male [MeSH], Adolescent [MeSH], Female [MeSH], Follow-Up Studies [MeSH], Response, Liver Neoplasms/diagnosis [MeSH], Adult [MeSH], Humans [MeSH], Carcinoma, Hepatocellular/diagnosis [MeSH], Carcinoma, Hepatocellular/pathology [MeSH], Survival Analysis [MeSH], Predictive Value of Tests [MeSH], Middle Aged [MeSH], Interleukin-8/blood [MeSH], Carcinoma, Hepatocellular/drug therapy [MeSH], Sorafenib/therapeutic use [MeSH], Europe/epidemiology [MeSH], Prognosis [MeSH], Young Adult [MeSH], Interleukin-6/blood [MeSH], Interleukin, Liver Neoplasms/drug therapy [MeSH], Young Adult, 03 medical and health sciences, 0302 clinical medicine, Predictive Value of Tests, Humans, Aged, Aged, 80 and over, Interleukin-6, Interleukin-8, Liver Neoplasms, Middle Aged, Prognosis, Survival Analysis, 3. Good health, Europe, Disease Progression, Female, Follow-Up Studies
Description: PurposeTo explore the potential correlation between baseline interleukin (IL) values and overall survival or objective response in patients with hepatocellular carcinoma (HCC) receiving sorafenib.MethodsA subset of patients with HCC undergoing sorafenib monotherapy within a prospective multicenter phase II trial (SORAMIC, sorafenib treatment alone vs. combined with Y90 radioembolization) underwent baseline IL-6 and IL-8 assessment before treatment initiation. In this exploratory post hoc analysis, the best cut-off points for baseline IL-6 and IL-8 values predicting overall survival (OS) were evaluated, as well as correlation with the objective response.ResultsForty-seven patients (43 male) with a median OS of 13.8 months were analyzed. Cut-off values of 8.58 and 57.9 pg/mL most effectively predicted overall survival for IL-6 and IL-8, respectively. Patients with high IL-6 (HR, 4.1 [1.9–8.9],p p = 0.009) had significantly shorter overall survival than patients with low IL values. Multivariate analysis confirmed IL-6 (HR, 2.99 [1.22–7.3],p = 0.017) and IL-8 (HR, 2.19 [1.02–4.7],p = 0.044) as independent predictors of OS. Baseline IL-6 and IL-8 with respective cut-off values predicted objective response rates according to mRECIST in a subset of 42 patients with follow-up imaging available (IL-6, 46.6% vs. 19.2%,p = 0.007; IL-8, 50.0% vs. 17.4%,p = 0.011).ConclusionIL-6 and IL-8 baseline values predicted outcomes of sorafenib-treated patients in this well-characterized prospective cohort of the SORAMIC trial. We suggest that the respective cut-off values might serve for validation in larger cohorts, potentially offering guidance for improved patient selection.
Document Type: Article
Other literature type
File Description: application/pdf; application/zip; text/xml
Language: English
ISSN: 1432-1335
0171-5216
DOI: 10.1007/s00432-021-03627-1
DOI: 10.17863/cam.80855
Access URL: https://link.springer.com/content/pdf/10.1007/s00432-021-03627-1.pdf
https://pubmed.ncbi.nlm.nih.gov/33855585
https://researchinformation.amsterdamumc.org/en/publications/baseline-interleukin-6-and-8-predict-response-and-survival-in-pat
https://pubmed.ncbi.nlm.nih.gov/33855585/
https://link.springer.com/content/pdf/10.1007/s00432-021-03627-1.pdf
https://www.research.manchester.ac.uk/portal/en/publications/baseline-interleukin6-and-8-predict-response-and-survival-in-patients-with-advanced-hepatocellular-carcinoma-treated-with-sorafenib-monotherapy(9acf0a43-982f-45c0-bd0f-93fe602b65cd).html
https://europepmc.org/article/MED/33855585
https://www.narcis.nl/publication/RecordID/oai%3Apure.amc.nl%3Apublications%2Fcb89262e-520c-4d45-8690-93a65ffaa752
https://pure.amsterdamumc.nl/en/publications/4b1fbf50-9abe-4ad5-9035-3fc453c662f2
https://doi.org/10.1007/s00432-021-03627-1
https://hdl.handle.net/10807/204116
https://doi.org/10.1007/s00432-021-03627-1
https://repository.publisso.de/resource/frl:6449874
https://www.repository.cam.ac.uk/handle/1810/333431
https://doi.org/10.17863/cam.80855
https://doi.org/10.1007/s00432-021-03627-1
Rights: CC BY
URL: http://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (http://creativecommons.org/licenses/by/4.0/) .
Accession Number: edsair.doi.dedup.....e6eafc3354eb76c7dd0de28edb0cde80
Database: OpenAIRE
Description
Abstract:PurposeTo explore the potential correlation between baseline interleukin (IL) values and overall survival or objective response in patients with hepatocellular carcinoma (HCC) receiving sorafenib.MethodsA subset of patients with HCC undergoing sorafenib monotherapy within a prospective multicenter phase II trial (SORAMIC, sorafenib treatment alone vs. combined with Y90 radioembolization) underwent baseline IL-6 and IL-8 assessment before treatment initiation. In this exploratory post hoc analysis, the best cut-off points for baseline IL-6 and IL-8 values predicting overall survival (OS) were evaluated, as well as correlation with the objective response.ResultsForty-seven patients (43 male) with a median OS of 13.8 months were analyzed. Cut-off values of 8.58 and 57.9 pg/mL most effectively predicted overall survival for IL-6 and IL-8, respectively. Patients with high IL-6 (HR, 4.1 [1.9–8.9],p p = 0.009) had significantly shorter overall survival than patients with low IL values. Multivariate analysis confirmed IL-6 (HR, 2.99 [1.22–7.3],p = 0.017) and IL-8 (HR, 2.19 [1.02–4.7],p = 0.044) as independent predictors of OS. Baseline IL-6 and IL-8 with respective cut-off values predicted objective response rates according to mRECIST in a subset of 42 patients with follow-up imaging available (IL-6, 46.6% vs. 19.2%,p = 0.007; IL-8, 50.0% vs. 17.4%,p = 0.011).ConclusionIL-6 and IL-8 baseline values predicted outcomes of sorafenib-treated patients in this well-characterized prospective cohort of the SORAMIC trial. We suggest that the respective cut-off values might serve for validation in larger cohorts, potentially offering guidance for improved patient selection.
ISSN:14321335
01715216
DOI:10.1007/s00432-021-03627-1